|
gptkbp:instanceOf
|
gptkb:androgen_ester
gptkb:synthetic_androgen
gptkb:anabolic_steroid
|
|
gptkbp:ATCCode
|
G03BA03
|
|
gptkbp:brand
|
gptkb:Android
Metandren
Oreton Methyl
Testred
|
|
gptkbp:CASNumber
|
58-18-4
|
|
gptkbp:chemicalFormula
|
C20H30O2
|
|
gptkbp:contraindication
|
gptkb:liver_disease
prostate cancer
pregnancy
breast cancer in men
|
|
gptkbp:derivedFrom
|
testosterone
|
|
gptkbp:discoveredBy
|
1935
|
|
gptkbp:eliminationHalfLife
|
2.5–3.5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:first_marketed
|
1936
|
|
gptkbp:IUPACName
|
17β-hydroxy-17α-methylandrost-4-en-3-one
|
|
gptkbp:KEGGID
|
gptkb:D00497
|
|
gptkbp:legalStatus
|
Schedule III controlled substance
|
|
gptkbp:medicalUse
|
treatment of breast cancer in women
treatment of delayed puberty in boys
treatment of male hypogonadism
|
|
gptkbp:MeSH_ID
|
D008767
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecular_structure_modification
|
17α-methyl group
|
|
gptkbp:molecularWeight
|
302.451 g/mol
|
|
gptkbp:pregnancyCategory
|
X
|
|
gptkbp:PubChem_CID
|
6281
6046
CHEMBL1200396
DB06710
|
|
gptkbp:relatedTo
|
gptkb:nandrolone
gptkb:oxandrolone
gptkb:stanozolol
testosterone
|
|
gptkbp:routeOfAdministration
|
oral
sublingual
buccal
|
|
gptkbp:sideEffect
|
hair loss
acne
liver toxicity
virilization
increased aggression
|
|
gptkbp:synonym
|
MT
17α-methyltestosterone
methylandrostenolone
|
|
gptkbp:UNII
|
70IYKD43PW
|
|
gptkbp:bfsParent
|
gptkb:M1T
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
methyltestosterone
|